Hormonal
GLP-1 receptor agonists (GLP-1-RAs) produce significant weight loss (up to 14.9%) and improved glycemic control (HbA1c reduction 0.8-1.8%) in adults with obesity or type 2 diabetes through mechanisms involving delayed gastric emptying, increased satiety, and glucose-dependent insulin secretion.
If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or liraglutide are highly effective. They work by mimicking a hormone that tells your brain you're full and slows down digestion. Expect some stomach upset at first, but starting with a low dose and increasing slowly helps. These drugs can lead to significant weight loss (around 15% in some cases) and better blood sugar control, especially if you have heart disease risk factors.
GLP-1-RAs function similarly to naturally occurring incretins. They stimulate insulin secretion in response to glucose levels, inhibit glucagon release, delay stomach emptying, and generate a sense of fullness via brain pathways. Head-to-head clinical studies have indicated that GLP-1-RAs outperform conventional antidiabetic medicines in terms of glycemic management and weight reduction.
Why this rating
The paper cites multiple large-scale randomized controlled trials (STEP-1, SUSTAIN-7, LEADER) and meta-analyses.
Source
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Khalid M Hamed et al. · Cureus · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →